| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director
3 companies
Siegall Clay B serves as a President and CEO at IMNM and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 12 buys and 3 sells. Those positions are worth an estimated $1.5M at current prices.
Historically, Siegall Clay B's trades have earned a strong insider score of 77/100 across 12 rated trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of +52.9%.
The biggest single holding is STTK (~$1.3M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 62,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2020 | RARE Ultragenyx Pharmaceutical Inc. | Director | Sale+OE | 34,750 | $85.37 | $2,966,735.66 | -93.2% |